Cargando…
COVID-19 and the neurological disease therapeutic pipeline
From the interruption of clinical trials by shelter-in-place orders to the challenges involved in safely collecting biofluid samples, drug development for neurological disease was hit hard by the COVID-19 pandemic this year. However, the field has responded with innovative solutions, and 2021 could...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7747002/ https://www.ncbi.nlm.nih.gov/pubmed/33340023 http://dx.doi.org/10.1038/s41582-020-00445-w |
| _version_ | 1783624907166318592 |
|---|---|
| author | Jicha, Gregory A. Abner, Erin L. |
| author_facet | Jicha, Gregory A. Abner, Erin L. |
| author_sort | Jicha, Gregory A. |
| collection | PubMed |
| description | From the interruption of clinical trials by shelter-in-place orders to the challenges involved in safely collecting biofluid samples, drug development for neurological disease was hit hard by the COVID-19 pandemic this year. However, the field has responded with innovative solutions, and 2021 could see the therapeutic pipeline flowing again. |
| format | Online Article Text |
| id | pubmed-7747002 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-77470022020-12-18 COVID-19 and the neurological disease therapeutic pipeline Jicha, Gregory A. Abner, Erin L. Nat Rev Neurol Year in Review From the interruption of clinical trials by shelter-in-place orders to the challenges involved in safely collecting biofluid samples, drug development for neurological disease was hit hard by the COVID-19 pandemic this year. However, the field has responded with innovative solutions, and 2021 could see the therapeutic pipeline flowing again. Nature Publishing Group UK 2020-12-18 2021 /pmc/articles/PMC7747002/ /pubmed/33340023 http://dx.doi.org/10.1038/s41582-020-00445-w Text en © Springer Nature Limited 2020 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
| spellingShingle | Year in Review Jicha, Gregory A. Abner, Erin L. COVID-19 and the neurological disease therapeutic pipeline |
| title | COVID-19 and the neurological disease therapeutic pipeline |
| title_full | COVID-19 and the neurological disease therapeutic pipeline |
| title_fullStr | COVID-19 and the neurological disease therapeutic pipeline |
| title_full_unstemmed | COVID-19 and the neurological disease therapeutic pipeline |
| title_short | COVID-19 and the neurological disease therapeutic pipeline |
| title_sort | covid-19 and the neurological disease therapeutic pipeline |
| topic | Year in Review |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7747002/ https://www.ncbi.nlm.nih.gov/pubmed/33340023 http://dx.doi.org/10.1038/s41582-020-00445-w |
| work_keys_str_mv | AT jichagregorya covid19andtheneurologicaldiseasetherapeuticpipeline AT abnererinl covid19andtheneurologicaldiseasetherapeuticpipeline |